A novel variant of estrogen receptor-alpha is expressed in ER-negative breast cancer and mediates membrane-initiated estrogen signaling

Xin-Tian Zhang,Shen Peng,Jiang Cao,Brian W. Loggie,Zhaoyi Wang

IF: 11.2

2005-01-01

Cancer Research

Abstract:1299 Since 1977, numerous studies have indicated the existence of a putative membrane-based estrogen receptor. However, the identity of this membrane-based estrogen receptor has not been established. Through an extensive homology search in Gene Bank, we recently identified and cloned a novel variant of ER-Α with a predicted molecular weight of 35.7 kDa. The transcript of this ER-Α variant is initiated from a previously unidentified promoter in the first intron of the original ER-Α gene. This ER-Α variant differs from the original ER-Α by lacking both transcriptional activation domains (AF-1 and AF-2) but retaining the dimerization, DNA-binding and partial ligand-binding domains. Its ligand-binding domain also possesses a unique 27 amino acid stretch that replaces the last 138 amino acids of the ER-Α. In transient transfection assays, this ER-Α variant exhibited no intrinsic transcriptional activity but strongly inhibited ligand-dependent and -independent transactivation activities mediated by the original ER-Α and ER-Β. Immunodetection and subcellular fractionation assays demonstrated that this ER-Α variant is expressed on the plasma membrane of mammary epithelial cells, and also in the cytoplasm and nucleus. In cells that express this ER-Α variant, 17Β-estradiol (E2) treatment activated a membrane-initiated effect of estrogen signaling by transiently activating the mitogen-activated protein kinase (MAPK) pathway that led to cell proliferation. Antiestrogens such as tamoxifen and ICI 182,780, however, strongly and persistently activated the MAPK pathway that then resulted in activation of the SAPK/JNK pathway. Immunohistochemistry analysis using a specific antibody aganst this ER-Α variant revealed that 26 of 38 cases (68%) breast cancer specimens examined express this ER-Αvariant on the plasma membrane and cytoplasm, and 12 out of 13 ER-negative breast caner specimens also express this ER-Α variant. Our findings demonstrate a physiologically important ER-Α variant that is involved in membrane-initiated estrogen signaling and suggest that aberrant expression of this ER-Α variant contributes to development of ER-positive and-negative human breast cancer.